Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for pediatric allergic asthma with type II inflammatory comorbidities
ChiCTR2600117113Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in allergic asthma, asthma, allergic rhinitis (AR) and 3 more, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Lung function test at week 48 and Total serum IgE at week 48. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthmaallergic rhinitis (AR)allergic conjunctivitis (AC)atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600117113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117113.